President Bush Names Niederhuber NCI Director

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 9
Volume 15
Issue 9

President Bush has appointed John E. Niederhuber, MD, as director of the National Cancer Institute (NCI). He is the Institute's 13th director, succeeding Andrew C. von Eschenbach, MD, who has been nominated as commissioner of the Food and Drug Administration (FDA).

WASHINGTON—President Bush has appointed John E. Niederhuber, MD, as director of the National Cancer Institute (NCI). He is the Institute's 13th director, succeeding Andrew C. von Eschenbach, MD, who has been nominated as commissioner of the Food and Drug Administration (FDA).

Dr. Niederhuber brings a wealth of experience to NCI, as a former cancer center director, former chair of the National Cancer Advisory Board (NCAB), member of the Institute's senior management team for the last year, and acting NCI director since June 2006. In addition to his NCI administrative duties, Dr. Niederhuber holds a clinical appointment as a member of the medical staff at the NIH Clinical Centers.

Dr. Niederhuber joined NCI in September 2005 as deputy director for translational and clinical sciences and almost immediately became NCI's chief operating officer after Dr. von Eschenbach was named FDA acting director.

Dr. Niederhuber came to NCI from the University of Wisconsin School of Medicine, where he served as professor of surgery and oncology and as director of its Comprehensive Cancer Center from 1997 to 2002. Dr. Niederhuber earned his medical degree at Ohio State University School of Medicine, Columbus.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content